HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Harkin Exit Intensifies Industry Need To Bolster Supplement Caucus

This article was originally published in The Tan Sheet

Executive Summary

One of DSHEA’s chief authors, Tom Harkin will retire from the Senate after 2014, pressuring supplement industry leaders to identify the next generation of congressional supporters. CRN’s Steve Mister says it will not be possible to replace the duo of Harkin and Orrin Hatch, who is retiring after 2018.

You may also be interested in...



In Brief

Sen. Hatch on path to re-election; Senate passes FDA Safety and Innovation Act; DSM petitions FDA for folic acid fortification of masa flour; Nutrition 21 returns under new management; ZO Skin Health defends trademarks; more news In Brief.

FDA Revision Of NDI Draft Guidance Starts With Grandfathered List

Trade groups say FDA committed to revisiting issues in the NDI draft guidance including how firms prove ingredients’ grandfathered status, notifications required for ingredients or finished products and data necessary to demonstrate NDI safety. The agency’s decision followed a meeting between industry allies Sens. Hatch and Harkin and FDA Commissioner Hamburg.

Dietary Supplement Caucus Goes Bicameral, Adds Hatch, Harkin As Co-Chairs

Sens. Orrin Hatch and Tom Harkin are no strangers to dietary supplement firms as longtime champions for their interests, but for the first time they are members of the industry's congressional caucus.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS123972

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel